INTRODUCTION
Cholesterol lowering to prevent major cardiovascular events in both asymptomatic individuals and patients with established vascular disease is one of the best-evidenced interventions in medicine. A raft of large-scale, well-conducted clinical trials comparing active treatment with placebo, or more versus less intensive therapy has shown the benefits of reducing circulating levels of LDL (Examples are [1] [2] [3] ; see [4, 5] for meta-analysis). This has led to the widespread use of statins, especially in secondary prevention and high-risk primary prevention and the promulgation of international treatment guidelines [6, 7] . However, concerns remain that are voiced in both the scientific and lay media [8] [9] [10] . These relate to side-effects and the size of the benefit in lower risk recipients, and this in turn may contribute to the incomplete uptake of, and adherence to, proven medication [11] .
The trials that comprise the evidence base were typically about 5 years in duration (ranging from 2.5 years in JUPITER [12] to 8 years in IMPROVE-IT [13] ). This is long enough to document clinical efficacy and detect early adverse events but because treatment is lifelong there have been questions over the size of the lifetime benefit and the risk of delayed onset diseases such as cancer. To address these issues, a number of investigating teams have extended the observation period with further follow-up of trial cohorts for 2 to 15 years [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] (see Table 1 ). The quality of long-term follow-up depends on resources, the availability of accessible death and hospital records and whether or not medication use is known after the end of the formal trial. Compromises have to be made in the rigour of the analyses but it is clear now that a consistent picture is emerging that is helpful in establishing the use of LDL lowering as well tolerated and highly effective prevention strategy.
METHODOLOGICAL APPROACHES
The core methodological approach in most of the extended follow-up studies is to interrogate national death registers which give cause-specific mortality rates. Further information has been derived from patient questionnaires sent at intervals after the conclusion of the double-blind period, review of case records by the investigating team, and increasingly interrogation of electronic health/hospital records. Depending on how comprehensive an evaluation was possible, post-trial use of lipid-lowering medication and relevant plasma (LDL) cholesterol levels may be known. The success and completeness of follow-up depends, therefore, on the stability of the population and accuracy of patient recall and of records collected for other purposes. Assumptions are usually made as to on going differential use of lipid-lowering drugs in the treatment arms of the original study, and the validity of surrogates (hospitalizations) for clinical events. The ideal scenario for long-term follow-up is where the placebo group continues to receive no active treatment. However, this is unlikely for ethical reasons (especially in the case of statins). A trial where a significant proportion of the placebo group does not take up therapy yields substantial information. On the contrary, exploration of studies where the majority of participants receive active treatment post-trial gives only short-term useful insight into legacy benefits because the difference in statin exposure diminishes with time.
A further issue as follow-up continues into old age is the impact of competing risk as prevention of early vascular disease that may have been fatal leads to the appearance of increased rates of nonvascular disease such as cancer or other disorders associated with ageing. This requires that statistical analyses take into account length of exposure and survivor bias.
KEY POINTS
Long-term follow-up of LDL-lowering trials demonstrates the safety of the intervention with no evidence for delayed onset of adverse outcomes such as cancer.
Relative risk reduction on statins persists beyond the end of the formal double-blind phase and in some studies is augmented in a post-treatment legacy benefit.
There can be the appearance of delayed benefits such as reduced risk of hospitalization because of heart failure. 
Potential mechanism for legacy benefit in LDL-lowering trials. This schema is based on the findings that in WOSCOPS long-term follow-up [20] and the ASCOT-LLA 2-year extension [21] there was a persistent risk reduction in the incidence of new events after the formal trial ended. However, in Heart Protection Study (HPS) [22] there was clear evidence that the risk reduction was attenuated almost immediately on cessation of differential treatment and by 2 years there was no evidence of a difference in incidence rates (see Figure 2 in [22] ). Likewise in 4S, during post-trial follow-up there appeared to be more coronary events (nonsignificant) in the patients allocated originally to simvastatin than those on placebo [17] . In the hypothetical trial depicted in the figure, the double-blind phase lasts 5 years and the period of extended observation, when patients receive similar levels of LDL-lowering therapy, is for a further 5 years. For the purposes of illustration, the LDL decrease is set at 1.0 mmol/l and the relative risk reduction at 22% (as per the CTTC analysis [5] ). Because WOSCOPS and ASCOT-LLA are primary prevention studies and 4S and HPS secondary prevention, it is suggested that the difference in response in terms of the size of the post-trial legacy benefit is related to the underlying severity of disease (although as noted above the extent of statin use post-trial may also be important). Thus, in patients with clinically manifest atherosclerotic vascular disease, there are a large number of complex lesions that are prone to rupture and the predominant effect of LDL lowering is to stabilise these. The data from HPS suggest either that stabilization is rapidly reversed and relative protection from further clinical events is lost within 12-24 months, or that post-trial statin use was so high that those originally on placebo caught up quickly with those originally on simvastatin. In patients with less severe disease -a mix of vulnerable plaque and precursor lesions such as fatty streaks -LDL-lowering therapy impacts on both pathological structures leading to stabilization of the plaque and regression/resolution of the lipid filled streaks. It takes a number of years before the fatty streaks reform and so there is a prolonged legacy benefit manifest in a post-trial relative risk reduction that lasts for a considerable period. This is of course a speculative mechanism and other factors may well explain the persistence of benefit in trials such as WOSCOPS. The stylized cumulative incidence curves can be compared with those found in [20] and [22] . CHD, coronary heart disease. 
NONSTATIN TRIALS: LONG-TERM FOLLOW-UP
During the course of the Coronary Drug Project conducted between 1966 and 1975, some treatment arms were terminated because of emergent serious adverse events and there was no clear result by the end of the randomized period. However, long-term follow-up revealed after 15 years an 11% decrease in mortality in niacin-treated patients compared with placebo [26] and this led to optimism that the agent would be useful in preventing coronary heart disease (CHD). Recent trials, unfortunately, did not bear out this supposition, at least when nicotinic acid was added to background statin therapy [27, 28] . Investigators from the Helsinki Heart Study (which was initiated in 1980 and compared a fibrate -gemfibrozil -with placebo in hypercholesterolemic men) published the results of a 3.5-year openlabel extension [14] and then an 18-year follow-up [19] . Over the full observation period, patients originally randomized to receive gemfibrozil experienced overall a 24% lower CHD mortality rate with greater effects seen in those at study initiation who had a raised triglyceride/low HDL profile (as in the original trial [29] ). The investigators reported also that younger patients (40-47 years) had a 42% reduction in CHD death rate compared with 24% in 48-57 year olds. This finding is in line with the postulate based on genomic and pharmacologic intervention studies that earlier intervention gives better results, possibly regardless of the agent used [30] . It is noted that gemfibrozil therapy was associated with an approximate 0.5 mmol/l reduction in LDL cholesterol and this should be borne in mind when evaluating this study alongside statin-based trials.
STATIN TRIALS: LONG-TERM FOLLOW-UP
Two major primary prevention trials -WOSCOPS [20] and ASCOT:LLA [21, 23] -have reported longterm follow-up morbidity and mortality data ( Table  1) . Other studies -PROSPER [25] and ALLHAT [24] included a substantial proportion of patients without prior overt signs or symptoms of CHD. It is in these lower risk groups that evaluation of extended observations is particularly pertinent because the decision to start LDL-lowering therapy depends on the perceived balance of benefit and risk both of which may occur years in the future.
Over 15 years of follow-up in the WOSCOPS trial [20] , we observed an apparent ever widening risk reduction for cardiovascular disease (CVD) outcomes, and for all-cause mortality a 12% decrease (P ¼ 0.03) across the total period. These results are replicated in the recently reported 20-year follow-up of this trial [31] . It was noteworthy that there was a significantly decreased risk of CHD-related death or hospitalization both during the 5 years of formal randomized therapy (33%, P < 0.001) and during the 10-year post-trial period (20%, P < 0.001)when both original treatment arms had the same level of statin use [20] . That is, there appeared to be a carry-forward or 'legacy' benefit arising from the initial 5 years of LDL lowering. No difference was seen over the 15 years of observation in noncardiovascular deaths or fatal/nonfatal cancers ( [20] , or even after 20 years -C.J. Packard and I. Ford, unpublished observation). The economics of LDL lowering with statins in WOSCOPS was explored using long-term data and it was reported [32 && ] that treatment of 1000 individuals with statin (for 5 years) saved the healthcare system £710 000 over the whole term. In this analysis, we noted also a late benefit in the form of a 43% (P ¼ 0.002) reduction in heart failure admissions in the original actively treated group.
ASCOT:LLA investigators examined the impact of LDL lowering on outcomes over extended observation periods of 2 years [21] and 11 years [23] . In the first report it was seen that despite equalization of LDL cholesterol levels because of high use of statins in both arms, the risk reduction for major coronary events was undiminished (at 37%, P ¼ 0.005) compared with the position at the end of the formal 3.3-year trial. Event rates in those initially assigned to statin continued to decline indicating as in WOSCOPS a legacy benefit. The 11-year extension used only mortality data. Here, it was found that all-cause mortality (similar to WOSCOPS at 15 years) was reduced by 14% (P ¼ 0.02) in patients originally in the statin arm and there was no difference in cancer deaths. However in ASCOT, reduced mortality appeared to be because of an impact on both cardiovascular and noncardiovascular deaths (mainly because of infection and respiratory disease). The mechanistic reasons for this are speculative [23] , and the finding may be confounded by small numbers of events and accuracy of attribution of cause of death.
Extended follow-up of the elderly cohort in the PROSPER trial [25] showed no difference over 8.6 years in all-cause mortality despite a 20% reduction in coronary death (P ¼ 0.009); there were compensating trends to increased strokes and noncardiovascular fatal outcomes in those allocated to active therapy. In the original PROSPER publication [33] , we reported increased cancer risk in the statintreated group but this difference diminished with time so that there was no significant excess cancers over the full observation period [25] . It was possible to follow both fatal and nonfatal events in the Scottish recruits. Here, the clear reduction in CHD risk during the 3.5 years of the trial [Hazard ratio (HR) 0.74, P ¼ 0.019] became a nonsignificant trend (HR 0.86, P ¼ 0.14) over the next 5.1 years. ALLHAT [24] provided long-term follow-up data (out to 8-13 years postrandomization) that largely reflected the main findings of the formal trial; that is, no overall reduction in CHD risk probably attributable to the small difference in LDL in the two treatment arms but a significant persistent benefit in black participants.
A 2-year post-trial follow-up of ALERT, a trial of fluvastatin therapy in renal transplant patients without a history of recent myocardial infarction, was published in 2005 [18] . It was a relatively small study with 2102 patients and therefore had limited power. Although LDL lowering produced a trend to benefit during the trial, it was only with extended follow-up that a significant result appeared. That is, over the entire 6.7 years, relative risk of a major coronary event was reduced 29% in the group assigned to statin.
A number of secondary prevention trials have been able to conduct long-term follow-up of both mortality and morbidity outcomes ( Table 1) . Heart Protection Study (HPS) was the largest trial of statin versus placebo and using annual survey questionnaires, investigators were able to determine event rates, statin use, and LDL levels during a 6-year posttrial period [22] . Over the total follow-up of 11 years in HPS, there was a substantial reduction in vascular events in the patients originally allocated to simvastatin, and as for other studies described above no emergent issues relating to cancer or noncardiovascular mortality. For a range of outcomes, the investigators were able to show that the benefits during the in-trial period (risk ratios for major coronary events and strokes of 0.73-0.77, all P < 0.0001) were not present in the extension (risk ratios of 0.93-0.98). Further, in a detailed year-by-year analysis (which was possibly due to the inherent power of the study), it could be seen that the differential rates for new major vascular events in the active versus placebo groups were established within 12 months of initiating therapy but at the end of the double-blind phase were lost within 12 months of both groups receiving the same treatment (selfreported statin use was the same at 59% rising to 84% in the post-trial period; LDL levels were also identical). This finding is in contrast to the reported risk reductions in the post-trial follow-up noted above for WOSCOPS and ASCOT.
Long-term follow-up findings in the 4S trial were reported using mortality data acquired at 2 and 5 years after the end of the formal study [15, 17] . 4S was the first statin trial to show a reduction in coronary and total mortality, and the 10.4-year extended observation period [17] reinforced the strength of the benefit with a 15% overall decrease in all-cause death (P ¼ 0.02) and a 24% fall in coronary death (P ¼ 0.0018). Splitting the in-trial and post-trial events, as in HPS, it was noted that the large risk reduction for coronary mortality during the trial (relative risk ¼ 0.57, P < 0.0001) was not present in the 5-year extension (relative risk ¼ 1.08). During the extension more than 80% of patients were taking open label statin.
In the LIPID trial, an extended follow-up was conducted for 2 years (making 8 years in total of observation) during which time face-to-face interviews were undertaken, and LDL cholesterol levels monitored and found to be equal in the two original treatment arms [16] . Morbidity and mortality outcomes were reported and in general the risk reductions seen in the formal trial persisted during the extension. All-cause mortality was reduced in patients originally assigned pravastatin by 22% in-trial and 18% (P ¼ 0.029) post-trial; CVD death rates were reduced 25% and 24%, respectively (P ¼ 0.019 for post-trial). Other endpoints, however, showed a smaller, nonsignificant risk reduction post-trial; the relative risk of CHD death and myocardial infarction was 24% (P < 0.0001) during the trial but 16% (P ¼ 0.08) in the extension; the respective figures for revascularization were 20% (P < 0.0001) and 16% (P ¼ 0.1).
Lv et al. [34 && ] have published recently a metaanalysis of outcome data from statin trials with extended follow-up. Attention was given to aggregate risk reductions at 2 years post-trial -a time point used in a number of studies, and total followup. Across the six studies included in the analysis, a significant risk reduction was seen for all-cause mortality at 2 years with a relative risk of 0.83 (0.74-0.93) but not for the total follow-up period, relative risk ¼ 0.94 (0.88-1.01). Major coronary events were reduced by 23% at 2 years [relative risk 0.77(0.63-0.95)] and by 14% for the total post-trial extension [relative risk 0.86(0.75-0.97)].
PATHOBIOLOGICAL BASIS OF LEGACY BENEFITS
Clearly, when LDL is lowered (using statins in the trials described above) there is a rapid reduction in risk of a coronary event that is established fully by about 12 months after starting treatment [4, 5] and continues during the period of active therapy. This benefit is proportional to the degree of LDL lowering as shown in regression analysis of all major trials [5] , including the recently reported IMPROVE-IT study using ezetimibe, a nonstatin LDL-lowering drug [13] . The pathobiological basis of risk reduction has been attributed to a combination of stabilization of vulnerable atherosclerotic plaques in coronary arteries and other vascular beds, and plaque regression (diminution in size) [35, 36] . The consistent finding that the risk reduction persists in a legacy benefit many years after differential treatment has ceased indicates that the intervention altered the 'natural history' of the disease process in those receiving active treatment and placed them on a new trajectory [37] .
A remarkable finding particularly in the primary prevention trials described above is that there was a risk reduction for new major coronary events even in the post-trial period. The size of the reduction was less than during the formal double-blind phase but contributed to an apparent continued 'widening' of the incidence (Kaplan-Meier) curves over a long period -15 years in the case of WOSCOPS. This additional risk reduction was not observed in HPS or 4S trials of secondary prevention.
It is tempting to speculate that an enhanced late benefit may be because of an effect of LDL-lowering beyond plaque stabilization which comes into play when atherosclerotic disease is less advanced. In the scheme shown in Fig. 1 , it is postulated that risk of an event is related to the probability of plaque rupture and that while the main response to LDL lowering is to stabilize plaque (an action that can occur rapidly but be reversed equally quickly), if there is less severe disease and a profusion of fatty streaks (the progenitors of more complex, fragile plaque) then LDL lowering resolves these precursor lesions and it is a number years before new streaks reappear to re-establish an elevated risk level.
In considering the phenomenon of carry-forward or legacy benefit in intervention studies, it is informative to look at the experience with other modalities. Maintenance of excellent glucose control in patients with type 2 diabetes in the UK Prospective Diabetes Study appears to be associated with a post-trial risk reduction for vascular disease [38] . Intriguingly, this was not seen for tight blood pressure control in the same trial [39] . Possibly, there are agents that impact on the natural history of CVD in a way that leads to legacy benefits while others have an effect that is more transient.
CONCLUSION
Extended observation from 2 to 10 years after LDLlowering trials completed their formal double-blind phase gives added confidence in the efficacy and safety of the intervention. There is no late appearance of serious adverse events (such as cancer), and indeed evidence of emergent late benefit in terms of risk of heart failure prevention [32 && ]. These data should increase confidence to initiate LDL-lowering therapy widely in lower risk individuals. Economic evaluations also need to be set in the framework of the long-term/lifetime impact of therapy and include recurrent and first events. This approach can yield a fuller picture of the net costs or savings to healthcare systems and remove perceived financial obstacles to effective prevention programmes.
In a new approach to presenting the benefits of intervention, it is now useful to consider assessment of both 'lifetime risk' (based possibly on the combination of informative gene scores and classical risk factors [40,41 & ]) and 'lifetime benefit' (based on long-term follow-up). The former provides an indication of exposure to integrated risk factors such as 'LDL-years' and the latter a measure of the reduction in total disease burden [37] . Clinically, application of these metrics will lead to earlier and more aggressive intervention especially in younger, asymptomatic people that will be personalized and cost-effective.
Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385:2264-2271. This study presents a novel approach to selecting patients for aggressive intervention using a CHD gene score (comprising 27 genetic variants) adjusted for classical risk factors. Cohort studies and primary and secondary prevention trials were included in the analysis. As gene score increased in the populations studied so did both relative and absolute risk reduction. For primary prevention trials, in those with the highest gene score the number-needed-to-treat to prevent 1 event was threefold less than in patients with the lowest score.
